Download PDF
Dialyse aktuell 2020; 24(02): 73-78
DOI: 10.1055/a-1022-8172
Schwerpunkt
© Georg Thieme Verlag Stuttgart · New York

Nierentransplantation

Grundlagen zu Ablauf, Immunsuppression und Nachsorge
Antonia Schuster
1   Abteilung für Nephrologie, Universitätsklinikum Regensburg
,
Bernhard Banas
1   Abteilung für Nephrologie, Universitätsklinikum Regensburg
,
Tobias Bergler
1   Abteilung für Nephrologie, Universitätsklinikum Regensburg
› Author Affiliations
Further Information

Publication History

Publication Date:
13 March 2020 (online)

Also available at
    Permissions and Reprints

ZUSAMMENFASSUNG

Über 60 Jahre nach der ersten langfristig erfolgreichen Nierentransplantation stellt diese heutzutage ein sicheres, etabliertes und effektives Therapiekonzept in der Versorgung terminal dialysepflichtiger Patienten dar. Grundlegende Voraussetzungen für eine erfolgreiche Nierentransplantation sind die Entschlüsselung relevanter immunologischer Fragen, die zunehmenden Möglichkeiten einer optimierten, auf den individuellen Patienten und sein immunologisches und nichtimmunologisches Risikoprofil abgestimmten immunsuppressiven Therapie und eine konsequente, qualifizierte Nachsorge. Gleichwohl gefährden der anhaltende und sich aggravierende Mangel an Spenderorganen und die damit einhergehende Zunahme an Wartezeit nicht nur die erreichbaren Erfolge nach Nierentransplantation, sondern in direkter Konsequenz auch das Leben betroffener Patienten.

 

  • Literatur

  • 1 Andrews PA, Burnapp L. British Transplantation Society/Renal Association UK Guidelines for Living Donor Kidney Transplantation 2018: Summary of Updated Guidance. Transplantation 2018; 102: e307 doi:10.1097/TP.0000000000002253
    CrossrefPubMedGoogle Scholar
  • 2 Davis CL. Preemptive transplantation and the transplant first initiative. Curr Opin Nephrol Hypertens 2010; 19: 592-597 doi:10.1097/MNH.0b013e32833e04f5
    CrossrefPubMedGoogle Scholar
  • 3 Dudley C, Harden P. Renal Association Clinical Practice Guideline on the assessment of the potential kidney transplant recipient. Nephron Clin Pract 2011; 118 (Suppl. 01) c209-c224 doi:10.1159/000328070
    CrossrefPubMedGoogle Scholar
  • 4 Wolfe RA, Ashby VB, Milford EL. et al Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725-1730 doi:10.1056/NEJM199912023412303
    CrossrefPubMedGoogle Scholar
  • 5 Tonelli M, Wiebe N, Knoll G. et al Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. Am J Transplant 2011; 11: 2093-2109 doi:10.1111/j.1600-6143.2011.03686.x
    CrossrefPubMedGoogle Scholar
  • 6 Lloveras J, Arcos E, Comas J. et al A paired survival analysis comparing hemodialysis and kidney transplantation from deceased elderly donors older than 65 years. Transplantation 2015; 99: 991-996 doi:10.1097/TP.0000000000000474
    CrossrefPubMedGoogle Scholar
  • 7 Pérez-Sáez MJ, Montero N, Redondo-Pachón D. et al Strategies for an Expanded Use of Kidneys From Elderly Donors. Transplantation 2017; 101: 727-745 doi:10.1097/TP.0000000000001635
    CrossrefPubMedGoogle Scholar
  • 8 Orandi BJ, James NT, Hall EC. et al Center-level variation in the development of delayed graft function after deceased donor kidney transplantation. Transplantation 2015; 99: 997-1002 doi:10.1097/TP.0000000000000450
    CrossrefPubMedGoogle Scholar
  • 9 Melih KV, Basak B, Mustafa C. et al Incidence, Risk Factors, and Outcomes of Delayed Graft Function in Deceased Donor Kidney Transplantation. Transplant Proc 2019; 51: 1096-1100 doi:10.1016/j.transproceed.2019.02.013
    CrossrefPubMedGoogle Scholar
  • 10 Kasiske BL, Zeier MG, Chapman JR. et al Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int 2010; 77: 299-311 doi:10.1038/ki.2009.377
    CrossrefPubMedGoogle Scholar
  • 11 Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 (Suppl. 03) S1-S155 doi:10.1111/j.1600-6143.2009.02834.x
    PubMedGoogle Scholar
  • 12 Ekberg H, Tedesco-Silva H, Demirbas A. et al ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562-2575 doi:10.1056/NEJMoa067411
    CrossrefPubMedGoogle Scholar
  • 13 Thomusch O, Wiesener M, Opgenoorth M. et al Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial. Lancet 2016; 388: 3006-3016 doi:10.1016/S0140-6736(16)32187-0
    CrossrefPubMedGoogle Scholar
  • 14 Hauch A, John M, Smith A. et al Generics: are all immunosuppression agents created equally?. Surgery 2015; 158: 1049-1054 doi:10.1016/j.surg.2015.05.024
    CrossrefPubMedGoogle Scholar
  • 15 Haller MC, Royuela A, Nagler EV. et al Steroid avoidance or withdrawal for kidney transplant recipients. Cochrane Database Syst Rev 2016: CD005632 doi:10.1002/14651858.CD005632.pub3
    PubMedGoogle Scholar
  • 16 Pascual J, Berger SP, Witzke O. et al TRANSFORM Investigators. Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation. J Am Soc Nephrol 2018; 29: 1979-1991 doi:10.1681/ASN.2018010009
    CrossrefPubMedGoogle Scholar
  • 17 Sommerer C, Suwelack B, Dragun D. et al An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients. Kidney Int 2019; 96: 231-244 doi:10.1016/j.kint.2019.01.041
    CrossrefPubMedGoogle Scholar
  • 18 Malvezzi P, Jouve T, Rostaing L. Costimulation Blockade in Kidney Transplantation: An Update. Transplantation 2016; 100: 2315-2323 doi:10.1097/TP.0000000000001344
    CrossrefPubMedGoogle Scholar
  • 19 Durrbach A, Pestana JM, Pearson T. et al A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010; 10: 547-557 doi:10.1111/j.1600-6143.2010.03016.x
    CrossrefPubMedGoogle Scholar
  • 20 Vincenti F, Charpentier B, Vanrenterghem Y. et al A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535-546 doi:10.1111/j.1600-6143.2009.03005.x
    CrossrefPubMedGoogle Scholar
  • 21 Rostaing L, Vincenti F, Grinyo J. et al Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study. Am J Transplant 2013; 13: 2875-2883 doi:10.1111/ajt.12460
    CrossrefPubMedGoogle Scholar
  • 22 Ristov J, Espie P, Ulrich P. et al Characterization of the in vitro and in vivo properties of CFZ533, a blocking and non-depleting anti-CD40 monoclonal antibody. Am J Transplant 2018; 18: 2895-2904 doi:10.1111/ajt.14872
    CrossrefPubMedGoogle Scholar
  • 23 Schiffer L, Hartleib-Otto M, Lerch C. et al [Challenges in Long-Term Follow-Up Care of Patients After Kidney Transplantation in Specialized Transplant Centers]. Gesundheitswesen 2019 Jun 11. doi:10.1055/a-0883-5218. [Epub ahead of print]
    PubMedGoogle Scholar
  • 24 Comai G, Ravaioli M, Baraldi O. et al Treatment of Acute Antibody-Mediated Rejection. Contrib Nephrol 2017; 190: 156-167 doi:10.1159/000468962
    PubMedGoogle Scholar
  • 25 Eskandary F, Regele H, Baumann L. et al A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection. J Am Soc Nephrol 2018; 29: 591-605 doi:10.1681/ASN.2017070818
    CrossrefPubMedGoogle Scholar
  • 26 Choi J, Aubert O, Vo A. et al Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients. Am J Transplant 2017; 17: 2381-2389 doi:10.1111/ajt.14228
    CrossrefPubMedGoogle Scholar
  • 27 Kasiske BL, Zeier MG, Chapman JR. et al Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int 2010; 77: 299-311 doi:10.1038/ki.2009.377
    CrossrefPubMedGoogle Scholar
  • 28 Cross NB, Webster AC, Masson P. et al Antihypertensives for kidney transplant recipients: systematic review and meta-analysis of randomized controlled trials. Transplantation 2009; 88: 7-18 doi:10.1097/TP.0b013e3181a9e960
    CrossrefPubMedGoogle Scholar
  • 29 Wanner C, Tonelli M. Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int 2014; 85: 1303-1309 doi:10.1038/ki.2014.31
    CrossrefPubMedGoogle Scholar
  • 30 Holdaas H, Jardine A. Acute renal allograft rejections, a role for statins?. Minerva Urol Nefrol 2003; 55: 111-119
    PubMedGoogle Scholar
  • 31 Palmer SC, Navaneethan SD, Craig JC. et al HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database Syst Rev 2014: CD005019 doi:10.1002/14651858.CD005019.pub4
    PubMedGoogle Scholar
  • 32 van Leeuwen MT, Grulich AE, Webster AC. et al Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation. Blood 2009; 114: 630-637 doi:10.1182/blood-2009-02-202507
    PubMedGoogle Scholar
  • 33 Cunningham J. Posttransplantation bone disease. Transplantation 2005; 79: 629-634 doi:10.1097/01.tp.0000149698.79739.ef
    CrossrefPubMedGoogle Scholar
  • 34 Kataria A, Magoon S, Makkar B. et al Machine perfusion in kidney transplantation. Curr Opin Organ Transplant 2019; 24: 378-384 doi: 10.1097/MOT.0000000000000675
    CrossrefPubMedGoogle Scholar
  • 35 Nangia G, Borges K, Reddy KR. Use of HCV-infected organs in solid organ transplantation: An ethical challenge but plausible option. J Viral Hepat 2019; 26: 1362-1371 doi:10.1111/jvh.13130
    CrossrefPubMedGoogle Scholar
  • 36 de Vera ME, Volk ML, Ncube Z. et al Transplantation of hepatitis C virus (HCV) antibody positive, nucleic acid test negative donor kidneys to HCV negative patients frequently results in seroconversion but not HCV viremia. Am J Transplant 2018; 18: 2451-2456 doi:10.1111/ajt.15031
    CrossrefPubMedGoogle Scholar
  • 37 Cooper DKC, Gaston R, Eckhoff D. et al Xenotransplantation-the current status and prospects. Br Med Bull 2018; 125: 5-14 doi:10.1093/bmb/ldx043
    CrossrefPubMedGoogle Scholar